Altamira Therapeutics (CYTO) Stock Price, News & Analysis

Company Overview

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

Key Stats

• Today's Range: $0.30 to $0.43
• 50-Day Range: $0.30 to $0.62
• 52-Week Range: $0.30 to $3.60
• Volume: 753,013 shs
• Average Volume: 697,326 shs
• Market Capitalization: $1.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Altamira Therapeutics Stock Analysis - MarketRank™

Altamira Therapeutics scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Altamira Therapeutics.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Altamira Therapeutics are expected to grow in the coming year, from ($2.65) to ($1.17) per share.

Price to Book Value per Share Ratio

Altamira Therapeutics has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.35% of the float of Altamira Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Altamira Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Altamira Therapeutics has recently decreased by 51.99%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Altamira Therapeutics does not currently pay a dividend.

Dividend Growth

Altamira Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.35% of the float of Altamira Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Altamira Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Altamira Therapeutics has recently decreased by 51.99%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.99

News Sentiment

Altamira Therapeutics has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Altamira Therapeutics this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for CYTO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Altamira Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Altamira Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.03% of the stock of Altamira Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.91% of the stock of Altamira Therapeutics is held by institutions.

CYTO Stock Analysis - Frequently Asked Questions

How have CYTO shares performed this year?

Altamira Therapeutics' stock was trading at $3.48 at the beginning of 2024. Since then, CYTO stock has decreased by 91.4% and is now trading at $0.30.
View the best growth stocks for 2024 here.

When did Altamira Therapeutics' stock split?

Altamira Therapeutics's stock reverse split before market open on Wednesday, December 13th 2023. The 1-20 reverse split was announced on Wednesday, December 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Altamira Therapeutics?

Shares of CYTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Altamira Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Altamira Therapeutics investors own include Plug Power (PLUG), Aridis Pharmaceuticals (ARDS), Soligenix (SNGX), Chemomab Therapeutics (CMMB), CNS Pharmaceuticals (CNSP), Cara Therapeutics (CARA) and Draganfly (DPRO).

Company Calendar

• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYTO
• CUSIP: N/A
• CIK: 1601936
• Web: www.aurismedical.com
• Phone: (441) 295-5950
• Fax: 41-61-201-1351
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.43
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $320,000.00
• Price / Sales: 3.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.56 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 3,401,000
• Free Float: 2,958,000
• Market Cap: $1.02 million
• Optionable: Not Optionable
• Beta: 1.80